Sam­sung Bioepis strikes deal for Ste­lara biosim­i­lar, but launch like­ly won't come in time for an IRA ex­emp­tion

Sam­sung Bioepis reached a deal this week that would al­low its Ste­lara biosim­i­lar hope­ful to launch in Feb­ru­ary 2025, adding to mount­ing com­pe­ti­tion against John­son …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER